|
| Press Releases |
|
 |
|
| Monday, June 3, 2024 |
|
|
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向け、革新的技術やサービスの発掘とそれを有するベンチャー企業の支援、将来的な提携を目的とし、2019 年に開始したベンチャー投資事業を強化し、継続することを決定しましたのでお知らせします。 more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物、海外製品名：「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
World's largest one stop jewellery marketplace attracts some 80,000 buyers, with growth in buyers from ASEAN, Korea and beyond
Mar 9, 2026 13:28 HKT/SGT
|
|
|
中國工業機器人龍頭埃斯頓於香港聯交所主板正式掛牌
Mar 9, 2026 11:44 HKT/SGT
|
|
|
Fosun International: One-Off Non-Cash Impairment Provisions for Certain Non-Core Businesses, Core Industries Maintain Sound Development Momentum
Mar 9, 2026 11:41: JST
|
|
|
LEXUS、ミラノデザインウィーク2026出展を発表
Mar 9, 2026 11:00: JST
|
|
|
富士通とＤＴアクシス、デジタルヘルスの発展を目指し、プログラム医療機器（SaMD）開発支援における協業を開始
Mar 9, 2026 10:50: JST
|
|
|
Fosun International: One-Off Non-Cash Impairment Provisions for Certain Non-Core Businesses, Core Industries Maintain Sound Development Momentum
Mar 9, 2026 11:41 JST
|
|
|
復星國際：對部分非核心業務一次性計提非現金減值 核心產業發展向好
Mar 9, 2026 10:34 HKT/SGT
|
|
|
AI Labs Introduces AI-Assisted Crypto Trading Platform Focused on Data Analysis and Automated Execution
Mar 9, 2026 09:40: JST
|
|
|
AI Labs Introduces AI-Assisted Crypto Trading Platform Focused on Data Analysis and Automated Execution
Mar 9, 2026 08:40 HKT/SGT
|
|
|
OMRON Healthcare releases new Women's Heart Health Factbook
Mar 9, 2026 06:00 HKT/SGT
|
|
|
World's largest one stop jewellery marketplace attracts some 80,000 buyers, with growth in buyers from ASEAN, Korea and beyond
Mar 8, 2026 21:04: JST
|
|
|
全球最大一站式珠寶商貿平台匯聚約80,000名買家 東盟、韓國等地買家見增長
Mar 8, 2026 20:04 HKT/SGT
|
|
|
全球最大一站式珠宝商贸平台汇聚约80,000名买家 东盟、韩国等地买家见增长
Mar 8, 2026 20:04 HKT/SGT
|
|
|
Shareholder-Exclusive Benefit! Shoucheng Holdings Launches Exclusive Entry Slots for Shareholders in the "2026 Beijing Yizhuang Half Marathon'' - Robot Marathon Becomes a New Carrier for Shareholder Benefits
Mar 8, 2026 18:00 HKT/SGT
|
|
|
股东专属福利！首程控股推出"2026北京亦庄半马"股东专属参赛名额 机器人马拉松成股东福利新载体
Mar 8, 2026 18:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
